Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Cancer, Volume 34, No. 4, Year 1974
Notification
URL copied to clipboard!
Description
Streptozotocin was administered to 106 patients with advanced malignancies. Therapeutic responses were observed in Hodgkin's disease, 7/16, lymphocytic lymphoma, 3/11, Burkitt's lymphoma, 1/12, and acute lymphocytic leukemia, 1/5. Two of 7 patients with islet cell carcinoma, 1 insulin‐secreting and 1 serotonin‐secreting, responded, but 8 patients with malignant carcinoid tumors originating from the ileum failed to demonstrate a reduction in either urinary 5‐hydroxyindole acetic acid or tumor mass. Additional evidence of drug activity was observed in 2 patients with melanoma and 1 of 8 cases with sarcoma. There was no apparent cross resistance between Streptozotocin, a methyl nitrosourea, and BCNU, a chloroethyl nitrosourea. Hematologic toxicity was observed in 9% of cases, whereas renal damage demonstrated in 28% was the principal treatment‐limiting drug effect. Ten to twenty percent of each total dose is excreted in the urine with an intact N‐nitroso group within 2 hours after administration. Recommended maximum doses based on results of these studies are 500 mg/m2 for 5 days or 1.5 g/m2/week in patients with normal renal function. Copyright © 1974 American Cancer Society
Authors & Co-Authors
Schein, Philips S.
United States, Rockville
National Cancer Institute Nci
United States, Washington, D.c.
Medstar Georgetown University Hospital
O'Connell, Michael J.
United States, Baltimore
Baltimore Cancer Research Center
Blom, Johannes
United States, Bethesda
Walter Reed National Military Medical Center
Hubbard, Susan P.
United States, Rockville
National Cancer Institute Nci
Magrath, Ian T.
Uganda, Kampala
Uganda Cancer Institute
Bergevin, Patrick R.
United States, Bethesda
Walter Reed National Military Medical Center
Wiernik, Peter H.
United States, Baltimore
Baltimore Cancer Research Center
Ziegler, John L.
Uganda, Kampala
Uganda Cancer Institute
DeVita, Vincent T.
United States, Rockville
National Cancer Institute Nci
Statistics
Citations: 179
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1002/1097-0142(197410)34:4<993::AID-CNCR2820340404>3.0.CO;2-T
ISSN:
0008543X
e-ISSN:
10970142
Research Areas
Cancer